Loading clinical trials...
Loading clinical trials...
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol C Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Conditions
Interventions
Ruxolitinib
Venetoclax
+4 more
Locations
33
Austria
St. Anna Kinderspital
Vienna, Austria
Universitair Ziekenhuis Gent
Ghent, Belgium
Rigshospitalet Copenhagen
Copenhagen, Denmark
Helsinki University Hospital, New Children's Hospital
Helsinki, Finland
Hôpital des Enfants GH Pellegrin - CHU de Bordeaux
Bordeaux, France
CHRU Lille - Hôpital Jeanne de Flandre
Lille, France
Start Date
October 1, 2025
Primary Completion Date
February 1, 2032
Completion Date
February 2, 2032
Last Updated
September 16, 2025
NCT05292664
NCT06316856
NCT05658640
NCT06034561
NCT05809284
NCT06025682
Lead Sponsor
Princess Maxima Center for Pediatric Oncology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions